Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 19;59(4):e03149-20.
doi: 10.1128/JCM.03149-20. Print 2021 Mar 19.

Quantitative Measurement of Anti-SARS-CoV-2 Antibodies: Analytical and Clinical Evaluation

Victoria Higgins  1 , Anselmo Fabros  2 , Vathany Kulasingam  3   2
Affiliations

Quantitative Measurement of Anti-SARS-CoV-2 Antibodies: Analytical and Clinical Evaluation

Victoria Higgins et al. J Clin Microbiol. .

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19). Molecular-based testing is used to diagnose COVID-19, and serologic testing of antibodies specific to SARS-CoV-2 is used to detect past infection. While most serologic assays are qualitative, a quantitative serologic assay was recently developed that measures antibodies against the S protein, the target of vaccines. Quantitative antibody determination may help determine antibody titer and facilitate longitudinal monitoring of the antibody response, including antibody response to vaccines. We evaluated the quantitative Roche Elecsys anti-SARS-CoV-2 S assay. Specimens from 167 PCR-positive patients and 103 control specimens were analyzed using the Elecsys anti-SARS-CoV-2 S assay on the cobas e411 (Roche Diagnostics). Analytical evaluation included assessing linearity, imprecision, and analytical sensitivity. Clinical evaluation included assessing clinical sensitivity, specificity, cross-reactivity, positive predictive value (PPV), negative predictive value (NPV), and serial sampling from the same patient. The Elecsys anti-SARS-CoV-2 S assay exhibited its highest sensitivity (84.0%) at 15 to 30 days post-PCR positivity and exhibited no cross-reactivity, a specificity and PPV of 100%, and an NPV between 98.3% and 99.8% at ≥14 days post-PCR positivity, depending on the seroprevalence estimate. Imprecision was <2% at 9.06 U/ml across 6 days, the negative quality control (QC) was consistently negative (<0.40 U/ml), the manufacturer's claimed limit of quantitation of 0.40 U/ml was verified, and linearity across the analytical measuring range was observed, except at the low end (<20 U/ml). Lastly, antibody response showed high interindividual variation in level and time of peak antibody titer and trends over time.

Keywords: COVID-19; SARS-CoV-2; antibody; antibody testing; immunoassays; infectious disease; serology; virology.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Total sensitivity and sensitivity for 0, 1 to 5, 6 to 14, 15 to 30, >30, 0 to 14, and ≥14 days post-PCR positivity for the quantitative Roche Elecsys anti-SARS-CoV-2 S assay using serum or plasma samples collected from 167 patients confirmed SARS-CoV-2 positive within the previous 0 to 73 days.
FIG 2
FIG 2
Anti-SARS-CoV-2 antibody response by days post-PCR positivity in five patients as measured by the quantitative Roche Elecsys anti-SARS-CoV-2 S assay.
See this image and copyright information in PMC

References

    1. Carter LJ, Garner LV, Smoot JW, Li Y, Zhou Q, Saveson CJ, Sasso JM, Gregg AC, Soares DJ, Beskid TR, Jervey SR, Liu C. 2020. Assay techniques and test development for COVID-19 diagnosis. ACS Cent Sci 6:591–605. doi:10.1021/acscentsci.0c00501. - DOI - PMC - PubMed
    1. Van Caeseele P, Bailey D, Forgie SE, Dingle TC, Krajden M, COVID-19 Immunity Task Force. 2020. SARS-CoV-2 (COVID-19) serology: implications for clinical practice, laboratory medicine and public health. CMAJ 192:E973–E979. doi:10.1503/cmaj.201588. - DOI - PMC - PubMed
    1. Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Spijker R, Taylor-Phillips S, Adriano A, Beese S, Dretzke J, Ferrante di Ruffano L, Harris IM, Price MJ, Dittrich S, Emperador D, Hooft L, Leeflang MM, Van den Bruel A, Cochrane COVID-19 Diagnostic Test Accuracy Group. 2020. Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev 6:CD013652. doi:10.1002/14651858.CD013652. - DOI - PMC - PubMed
    1. Long Q-X, Liu B-Z, Deng H-J, Wu G-C, Deng K, Chen Y-K, Liao P, Qiu J-F, Lin Y, Cai X-F, Wang D-Q, Hu Y, Ren J-H, Tang N, Xu Y-Y, Yu L-H, Mo Z, Gong F, Zhang X-L, Tian W-G, Hu L, Zhang X-X, Xiang J-L, Du H-X, Liu H-W, Lang C-H, Luo X-H, Wu S-B, Cui X-P, Zhou Z, Zhu M-M, Wang J, Xue C-J, Li X-F, Wang L, Li Z-J, Wang K, Niu C-C, Yang Q-J, Tang X-J, Zhang Y, Liu X-M, Li J-J, Zhang D-C, Zhang F, Liu P, Yuan J, Li Q, Hu J-L, Chen J, et al. 2020. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med 26:845–848. doi:10.1038/s41591-020-0897-1. - DOI - PubMed
    1. Kofler N, Baylis F. 2020. Ten reasons why immunity passports are a bad idea. Nature 581:379–381. doi:10.1038/d41586-020-01451-0. - DOI - PubMed

Substances

LinkOut - more resources